Human Amniotic-Derived Mesenchymal Stem Cells
Efficacy
The First Affiliated Hospital with Nanjing Medical UniversityCell therapyEarly Phase 1Active
C
38/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 81/ 100
Competitive context
23 Active assets in the Efficacy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE Shandong Provincial Hospital | Phase 4 | BB |
Metformin Xijing Hospital | Phase 4 | BB |
Pioglitazone Xijing Hospital | Phase 4 | B |
gv-971 First Affiliated Hospital Xi'an Jiaotong University | Phase 4 | B |
Inno-206 Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 4 | B |
View all 37 →
Same molecule, other indications
Human Amniotic-Derived Mesenchymal Stem Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →